Valuation: Beta Bionics, Inc.

Market Cap 753M 652M 615M 558M 1.05B 72.14B 1.06B 7.35B 2.83B 36.6B 2.83B 2.76B 116B P/E 2026 *
-7.87x
P/E 2027 * -7.56x
Enterprise Value 619M 536M 506M 459M 861M 59.33B 868M 6.04B 2.33B 30.1B 2.32B 2.27B 95.68B EV / Sales 2026 *
4.76x
EV / Sales 2027 * 3.79x
Free-Float
98.89%
Yield 2026 *
-
Yield 2027 * -
1 week-14.04%
Current month-16.21%
1 month-4.78%
3 months+15.15%
6 months+60.69%
Current year-45.09%
1 week 15.85
Extreme 15.85
19.51
1 month 15.85
Extreme 15.85
20.66
Manager TitleAgeSince
Chief Executive Officer 50 15/08/2022
Director of Finance/CFO 37 01/08/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 57 01/02/2020
Director/Board Member 50 15/08/2022
Director/Board Member 63 01/10/2024
Change 5-day change 1-year change 3-year change Capi.($)
+0.78%-14.70%-36.77% - 745M
+0.62%-0.03%+27.98%+19.00% 225B
+1.55%-2.12%+6.95%-19.82% 141B
+2.38%+3.07%-15.95%+24.43% 130B
+4.82%-5.75%-56.14%-14.87% 62.29B
+1.99%+0.96%-18.12%-13.93% 49.39B
+1.36%-4.87%+10.25%+15.54% 48.63B
-0.09%-2.69%+19.12%+27.79% 41.42B
+0.41%+0.15%+38.80%+50.73% 40.12B
+2.16%-2.35%-17.45%+51.04% 31.23B
Average +1.69%-2.00%-4.13%+15.54% 85.52B
Weighted average by Cap. +1.58%-1.31%+4.01%+11.18%

Financials

2026 *2027 *
Net sales 130M 113M 106M 96.53M 181M 12.47B 182M 1.27B 490M 6.33B 489M 478M 20.11B 179M 156M 147M 133M 250M 17.2B 252M 1.75B 675M 8.73B 674M 659M 27.74B
Net income -95.03M -82.34M -77.71M -70.5M -132M -9.11B -133M -928M -358M -4.62B -357M -349M -14.69B -99.27M -86.02M -81.18M -73.64M -138M -9.51B -139M -970M -374M -4.83B -373M -365M -15.35B
Net Debt -134M -116M -109M -99.19M -186M -12.82B -187M -1.31B -503M -6.5B -502M -491M -20.67B -73.32M -63.53M -59.96M -54.39M -102M -7.03B -103M -716M -276M -3.57B -275M -269M -11.33B
Logo Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Employees
-
Date Price Change
14/09/26 USD 16.72 +0.78%
11/09/26 USD 16.59 0.00%
10/09/26 USD 16.59 -4.82%
09/09/26 USD 17.43 -9.88%
08/09/26 USD 19.34 -0.57%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
16.73USD
Average target price
21.22USD
Spread / Average Target
+26.83%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!